BMS-195614
BMS-195614 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of cardiovascular disease and hypertension. It is a member of the class of drugs known as angiotensin II receptor antagonists, which are commonly used to manage high blood pressure and heart failure.
Mechanism of Action[edit | edit source]
BMS-195614 functions by selectively blocking the angiotensin II receptor type 1 (AT1 receptor). Angiotensin II is a potent vasoconstrictor, meaning it narrows blood vessels, which increases blood pressure. By inhibiting the action of angiotensin II at the AT1 receptor, BMS-195614 helps to relax blood vessels, thereby lowering blood pressure and reducing the workload on the heart.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of BMS-195614 includes its absorption, distribution, metabolism, and excretion characteristics. It is typically administered orally, and its bioavailability can be affected by factors such as food intake and individual metabolic differences. The drug is metabolized primarily in the liver and excreted via the kidneys.
Clinical Trials[edit | edit source]
BMS-195614 has been evaluated in several clinical trials to assess its efficacy and safety in treating hypertension and other cardiovascular conditions. These studies have generally shown that BMS-195614 is effective in reducing blood pressure with a favorable safety profile. However, as with any medication, there are potential side effects, including dizziness, headache, and fatigue.
Side Effects[edit | edit source]
Common side effects of BMS-195614 include:
- Dizziness
- Headache
- Fatigue
- Nausea
Less common but more serious side effects may include:
- Hyperkalemia (elevated potassium levels)
- Renal impairment
- Hypotension (abnormally low blood pressure)
Research and Development[edit | edit source]
BMS-195614 was developed by Bristol-Myers Squibb, a pharmaceutical company known for its research in cardiovascular therapies. The development of BMS-195614 is part of a broader effort to create more effective and safer treatments for hypertension and related conditions.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
